Plot The spread of a new strain of coronavirus “omicron”
The American company Moderna plans to begin clinical trials of a booster vaccine against the omicron strain in early 2022, the company’s press service said.
Preliminary studies have shown that the prototype created on the basis of the existing mRNA-1273 vaccine protects well against the new strain. For example, a dose of 50 mcg approximately 37 times increases the level of neutralizing antibodies to omicron, a dose of 100 mcg up to 83 times.
“Moderna’s data show that the currently approved booster can increase the level of neutralizing antibodies by 37 times compared to the levels before the increase, and this is encouraging,” said Stefan Bankel, chief executive officer of the biotechnology company Moderna.
He clarified that clinical trials of the booster vaccine will start early next year.
Earlier, the head of the NITSEM named after Gamalei, Alexander Ginzburg, announced the effectiveness of the “V Satellite” from the omicron strain, subject to revaccination by the “Light Satellite” six months after vaccination by the “V Satellite”.